Valvular heart disease associated with benfluorex therapy: High prevalence in patients with unexplained restrictive valvular heart disease

European Journal of Echocardiography

Volumn 12, Issue 9, 2011, Pages 688-695

  Boudes, Audrey ^a   Lavoute, Cécile ^a   Avierinos, Jean François ^a   Dolley, Yvan Le ^a   Villacampa, Chloe ^a   Salem, Adrien ^a   Loundou, Anderson Dieudonné ^a   Michel, Nicolas ^a   Renard, Sébastien ^a   Habib, Gilbert ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Appetite suppressants; Benfluorex; Valve disease

Indexed keywords

ANOREXIGENIC AGENT; BENFLUOREX; ANTILIPEMIC AGENT; DRUG DERIVATIVE; FENFLURAMINE;

ADULT; AORTA DISEASE; AORTA VALVE; AORTA VALVE DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DRUG EXPOSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART VALVE STENOSIS; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; MITRAL VALVE; MITRAL VALVE DISEASE; PREVALENCE; PRIORITY JOURNAL; RESTRICTIVE VALVULAR HEART DISEASE; SEX DIFFERENCE; TRICUSPID VALVE; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; MIDDLE AGED;

AORTIC VALVE; APPETITE DEPRESSANTS; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MITRAL VALVE;

EID: 84856023420     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jer116     Document Type: Article

References (23)

1. Frachon I, Etienne Y, Jobic Y, Gal GL, Humbert M, Leroyer C. Benfluorex and unexplained valvular heart desease: a case-control study. PLoS One 2010;5: e10128.
2. Tribouilloy C, Rusinaru D, Henon P, Tribouilloy L, Leleu F, Andréjak M. Restrictive organic mitral regurgitation associated with benfluorex therapy. Eur J Echocardiogr 2010;11:614-21.
3. Le Ven F, Tribouilloy C, Habib G, Gueffet JP, Maréchaux S, Eicher JC et al. Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Eur J Echocardiogr 2011;12:265-71.
4. Boutet K, Frachon I, Jobic Y, Gut-Gobert C, Leroyer C, Carlhant-Kowalski D. Fenfluaramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009; 33:684-8.
5. Khan M, Herzog C, St. Peter J, Hartley G, Madlon-Kay R, Dick C et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339: 713-8. (Pubitemid 28417353)
6. Graham D, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:635. (Pubitemid 27360767)
7. Weissman N, Tighe J, Gottdiener J, Gwynne J. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998;339:725-32. (Pubitemid 28417355)
8. Jick H, Vasilakis C, Weinrauch L, Meier C, Jick S, Derby L. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24. (Pubitemid 28417354)
9. Connoly H, McGoon M, Hensrud M, Edwards B, Edwards W, Schaff H. Valvular heart disease associated with fenfluramine-phentermine. N Engl J 1997;337: 581-8. (Pubitemid 27360757)
10. Pellikka P, Tajik A, Khandheria B, Seward J, Callahan J, Pitot H et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-96. (Pubitemid 23110391)
11. Noize P, Sauer M, Bruneval P, Moreau M, Pathak A, Bagheri H. Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol 2006;20: 577-8. (Pubitemid 44762174)
12. Gustafsson B, Tommeras K, Nordrum I, Loennechen J, Brunsvik A, Solligard E et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005;111:1517-22. (Pubitemid 40470647)
13. Weill A, Païta M, Tuppin P, Fagot J, Neumann A, Simon D et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf 2010;19:1256-62.
14. Schade R, Andersohn F, Suissa S, HaverkampW, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. (Pubitemid 46041751)
15. Bana D, MacNeal P, LeCompte P et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974;640.
16. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9. (Pubitemid 47243713)
17. Waller E, Kaplan J, Heckman M. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005;80:1016-20. (Pubitemid 41099387)
18. Lancellotti P, Moura L, Pierard L, Agricola E, Popescu B, Tribouilloy C et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiograph 2010;11:307-32.
19. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Philippatos G. Guidelines on the management of valvular heart disease. Eur Heart J 2007;28: 230-68.
20. Mitchell P, Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord 1990;19:43-51. (Pubitemid 20141160)
21. Droogmans S, Kerkhove D, Cosyns B, Van Camp G. Role of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr 2009;10:467-76.
22. Setola V, Dukat M, Glennon R, Roth B. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol 2005;68:20-33. (Pubitemid 41002941)
23. Shively B, Roldan C, Gill E, Najarian T, Loar S. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100: 2161-7.